Ony Infasurf Claims Dinged By FDA After Firm Challenges Rival’s Study
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA sent an untitled letter to Ony objecting to web pages and “blurry” video text that imply its lung surfactant is superior to competing products and minimizes Infasurf’s risks; Ony sued Cornerstone last year over its superiority claims.
You may also be interested in...
For Discovery’s Surfaxin, Another Delay
Discovery Labs delays the commercial launch of its RDS drug Surfaxin until 2Q 2013, but continues to look for an international partner for the rest of its pipeline. The company assures investors that the delay is not indicative or safety or efficacy problems.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.